Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712787 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 364
- Enrollment target
NCT03712787: Clinical Trial Phase 2 study, sponsored by AbbVie.
NCT03712787 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 364 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (174% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03712787, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 364 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in participants with early AD.
Primary Outcome
Treatment emergent adverse events (TEAEs) are defined as any adverse event (AE) from the time of study drug administration until 20 weeks after discontinuation of study drug. An AE is defined as any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE (SAE) is defined as any event that: results in death; is life-threatening; results in hospitalization or prolongation of hospitalization; is a congenital anomaly; results in persistent or s
Interventions
- DRUG Tilavonemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 2 |
Why NCT03712787 stopped before completion
NCT03712787 is an interventional study that assigns participants to a tested intervention. The registered 364 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (174% higher).
The record links to 0 conditions, and to 1 intervention - of which Tilavonemab is the first listed.
NCT03712787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03712787 about?
NCT03712787 is a clinical study titled "An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)". The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in participants with early AD.
What is the current status of trial NCT03712787?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 364 participants. The study started on 2019-03-22. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT03712787?
The interventions under investigation include: Tilavonemab (DRUG).
Who is sponsoring clinical trial NCT03712787?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03712787's enrollment target sits among peer trials
364 121st of 2000 higher than 1,879 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05330221 · 364 participants · NA
Project 2: ACHIEVE- HF
- NCT05673148 · 364 participants · Phase 3
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI